CROI 2015: Week-on, Weekend-Off HIV Treatment Controls Viral Load in Young People

alt

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on 2 days over the weekend was just as effective as daily treatment at controlling viral load in an 11-country trial of adolescents and young people, Karina Butler from Our Lady’s Children’s Hospital in Dublin reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

[Produced in collaboration with Aidsmap]

SEE ALSO: Weekends Off Treatment Work Well for Some Young People with HIV [VIDEO]

Sustaining adherence to daily treatment appears to be more difficult for young adults and adolescents. Studies of adherence show consistently that older age is strongly correlated with better adherence, and clinicians in Europe, North America, and sub-Saharan Africa have reported the difficulties faced by adolescents in taking medication regularly.

"As pediatric treaters we’re desperate for new ways of supporting adherence," Elaine Abrams of Columbia University in New York told a press conference reviewing the study results.

The BREATHER study was designed to test a regimen that could normalize life for young people, said Butler.

"Adolescents going out on the weekend often don't take their medication because they don’t want people to see them taking it," she said. The prospect of lifelong therapy is also daunting for many young people.

"The principle of this study was quite different [from treatment interruption studies in which] you were allowing viral rebound, whereas in this study you were taking a break from taking medication," Butler told the press conference.

Interrupting treatment for prolonged periods is not recommended; a large international study called SMART found that people who interrupted treatment had a higher risk of death and serious illness, both AIDS-related and non-AIDS related. Studies of shorter periods of treatment interruption, of fixed duration, have also shown that stopping treatment for a month or week at a time results in a higher risk of viral rebound.

However, the durability of a 5 days on/2 days off regimen has not been tested in a large trial, and it is plausible that treatment based on drugs that take a long time to clear from the blood, such as efavirenz (Sustiva), would be less likely to result in viral rebound if doses are missed on 2 consecutive days, provided that viral load has already been suppressed for a prolonged period. 

A study of 221 patients found that after 1 year of viral suppression, the risk of viral rebound declined substantially in people who were not fully adherent to treatment.

The BREATHER study recruited 199 young people between the ages of 8 and 24 (median age 14) in Europe, Uganda, Thailand, Argentina, and the U.S. 21% were age 18 or over. Young people were eligible to join the study if they had been on stable antiretroviral therapy with viral load below 50 copies/mL for 12 months and if they had never experienced viral rebound.

Participants were randomly assigned to receive either "short cycle" treatment, during which they took 2 consecutive days off treatment each week (usually Saturday and Sunday), or continuous treatment.

After a median of 85 weeks of follow up, viral load had rebounded above 50 copies/mL in 6 people in the short cycle group and 7 in the continuous treatment group.

The weekend-off regimen proved highly acceptable to young people, with 74% saying that it made life a "lot" easier, although when questioned about a range of everyday activities that might be difficult as a result of treatment, the only area of statistically significant improvement was "going out with friends." Participants who stopped treatment on the weekend said that side effects lessened during the break and they were also more prone to report previously undisclosed side effects.

Participants in the weekend-off arm were less likely to change treatment for reasons of toxicity or simplification during the study, but there was no significant difference in the reporting of adverse events related to treatment.

Experts stressed that these results should be treated with caution, and that young people should not begin missing weekend doses until longer-term follow-up of the participants in this study has provided reassurance that the strategy is safe. In particular, they stressed that the results apply only to young people taking efavirenz-based treatment who had undetectable viral load and no previous history of viral rebound.

Young people who took part in the study expressed concern that others might try doing the same thing without proper monitoring and end up falling ill.

"It’s important to highlight that they were a very select group of suppressed patients," said Abrams.

"It’s important to say that they had never failed treatment before. They were the best group of individuals to enter such a study," Butler agreed. Many adolescents with a long history of HIV treatment are likely to have experienced several episodes of viral rebound, leading to the development of drug resistance. Lower levels of antiretrovirals during the weekend off treatment might not be sufficient to suppress drug-resistant virus in those young people with a history of multiple treatment failures, leading to viral rebound and further drug resistance.

"I don’t think results of this study should impact on clinical practice," said Butler. "Clearly we need to look at long-term follow up to see that it is safe." However, she went on, "if there are individual circumstances a clinician may choose to change treatment, with careful monitoring."

2/25/15

Reference

K Butler for BREATHER Trial Team. ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 38LB.